Variables No. of patients Mean survival (months) 14 months PFS proportion (%) P value
Concurrent methylation status of  all three MGMT, TP53 and CDKN2A MMM 6 13.20(11.80-14.60) 80 0.131
UUU 5 10.60(6.86-14.34) 30
Combinations of prognostic analysis of concurrent MGMT:TP53 methylation M     M 10 11.44(8.75-14.13) 68.6 0.172
U      U 8 9.25(5.84-12.66) 25
Combinations of prognostic analysis of concurrent MGMT:CDKN2A methylation M     M 13 12.72(11.41-14.04) 55 0.352
U      U 8 10.36(7.02-13.73) 41.7
Combinations of prognostic analysis of concurrent TP53: CDKN2A methylation M     M 7 11.88(9.22-14.56) 68.6 0.479
U      U 24 11.79(10.35-13.24) 60.2
Table 4: Univariate analysis with concurrent methylation.